Vol 7, No 3 (2022)
Letter to the Editor
Published online: 2022-09-07
Intranasal vaccines: a panacea to vaccine hesitancy?
12
Medical Research Journal 2022;7(3):274-275.
Abstract
Not available
References
- Freeman D, Lambe S, Yu LM, et al. Injection fears and COVID-19 vaccine hesitancy. Psychol Med. 2021 [Epub ahead of print]: 1–11.
- Hassan AO, Shrihari S, Gorman MJ, et al. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 2021; 36(4): 109452.
- Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998; 338(20): 1405–1412.
- Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 2004; 350(9): 896–903.
- van der Ley PA, Zariri A, van Riet E, et al. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. Front Immunol. 2021; 12: 781280.